A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.

Abstract

Current choices of second-line chemotherapy regimens for patients with advanced non-small-cell lung cancer (NSCLC) are extremely limited. We applied a new strategy of using nab-paclitaxel as single chemotherapy regimen in second-line setting for patients with unsuccessful first-line chemotherapy. The efficacy and safety were compared with patients who… (More)
DOI: 10.1007/s12032-015-0660-5

Topics

Cite this paper

@article{Liu2015API, title={A phase II open-label clinical study of comparing nab-paclitaxel with pemetrexed as second-line chemotherapy for patients with stage IIIB/IV non-small-cell lung cancer.}, author={Zhefeng Liu and Zhimin Wei and Yi Hu and Feng Gao and Lu Hao and Ping Fang and Shengjie Sun and Jinyu Li and Shunchang Jiao}, journal={Medical oncology}, year={2015}, volume={32 8}, pages={216} }